These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 186874)

  • 21. The current status and future prospects of treatment for multiple myeloma.
    Durie BG; Salmon SE
    Clin Haematol; 1982 Feb; 11(1):181-210. PubMed ID: 6176381
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of plasma cell myeloma with cytotoxic agents.
    Bergsagel DE; Pruzanski W
    Arch Intern Med; 1975 Jan; 135(1):172-6. PubMed ID: 803363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Amylosis of the nerve in Kahler's disease].
    Buge A; Escourolle R; Poisson M; Rancurel G; Hauw JJ
    Ann Med Interne (Paris); 1974 Apr; 125(4):359-63. PubMed ID: 4433098
    [No Abstract]   [Full Text] [Related]  

  • 24. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
    Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
    Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
    [No Abstract]   [Full Text] [Related]  

  • 25. [Progress and results in the treatment of multiple myeloma].
    Clauvel JP
    Bull Cancer; 1972; 59(4):405-16. PubMed ID: 4592093
    [No Abstract]   [Full Text] [Related]  

  • 26. Sequential therapy compared with combination therapy in multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):163-71. PubMed ID: 1111465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.
    Kyle RA; Gailani S; Seligman BR; Blom J; McIntyre OR; Pajak TF; Holland JF
    Cancer Treat Rep; 1979 Aug; 63(8):1265-9. PubMed ID: 476704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma cell myeloma. An interpretive review.
    Bergsagel DE
    Cancer; 1972 Dec; 30(6):1588-94. PubMed ID: 4565818
    [No Abstract]   [Full Text] [Related]  

  • 29. [Therapeutic experiences in multiple myeloma].
    Sonntag R; Favre E; Martz G
    Schweiz Med Wochenschr; 1972 Nov; 102(44):1588-9. PubMed ID: 4566555
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
    Frei E; Schabel FM; Goldin A
    Cancer Res; 1974 Jan; 34(1):184-93. PubMed ID: 4520419
    [No Abstract]   [Full Text] [Related]  

  • 31. [Therapy of malignant gammopathies].
    Emmerich B
    Dtsch Med Wochenschr; 1984 Jan; 109(1):26-30. PubMed ID: 6420138
    [No Abstract]   [Full Text] [Related]  

  • 32. [Monoclonal gammapathy of indeterminate origin and myeloma].
    Bury J; Salmon J; Fillet G
    Rev Med Liege; 1988 Apr; 43(8):270-4. PubMed ID: 3285431
    [No Abstract]   [Full Text] [Related]  

  • 33. Primary treatment of disseminated Hodgkin's disease with BCNU alone and in combination with vincristine, procarbazine, and prednisone.
    Harrison DT; Neiman PE
    Cancer Treat Rep; 1977 Aug; 61(5):789-95. PubMed ID: 329978
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Survival and therapy of multiple myeloma. Apropos of 56 observed cases].
    Locatelli F; Giovanelli E; Neretto G; Furno F; Pellerito R
    Minerva Med; 1979 Mar; 70(13):925-33. PubMed ID: 220567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy for multiple myeloma.
    Alexanian R; Salmon S; Bonnet J; Gehan E; Haut A; Weick J
    Cancer; 1977 Dec; 40(6):2765-71. PubMed ID: 589554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Progress in combination chemotherapy of malignant lymphomas (author's transl)].
    Senn HJ
    Schweiz Rundsch Med Prax; 1973 Dec; 62(51):1589-94. PubMed ID: 4771027
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapy of multiple myeloma. Italian Multiple Myeloma Study Group.
    Boccadoro M; Avvisati G; Cantonetti M; Cavo-Comotti BM; Frieri R; Gallamini A; Gallone G; Lauta VM; Liberati M; Marmont F
    Pathol Biol (Paris); 1990 Oct; 38(8):829. PubMed ID: 2274374
    [No Abstract]   [Full Text] [Related]  

  • 39. [Value of successive chemotherapy in multiple myeloma of bone. Prospective study over 4 years].
    Bataille R; Morlock G; Rosenberg F; Lopitaux R; Blotman F; Sany J; Ciurana AJ; Rampon S; Bussière JL; Simon L; Serre H
    Rev Rhum Mal Osteoartic; 1980 Feb; 47(2):77-82. PubMed ID: 7361063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol).
    Case DC; Sonneborn HL; Paul SD; Hayes DM; Dorsk BM; Carroll RJ; Bove L
    Oncology; 1985; 42(3):137-40. PubMed ID: 3858763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.